Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes

BN Sağlık, S Ilgın, Y Özkay - European journal of medicinal chemistry, 2016 - Elsevier
Abstract Donepezil (DNP), an acetylcholinesterase (AChE) inhibitor, is one of the most
preferred choices in Alzheimer diseases (AD) therapy. In the present study, 38 new DNP …
被引用次数：107 相关文章

Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes

B SAĞLIK, S ILGIN, Y ÖZKAY - EUROPEAN JOURNAL OF …, 2016 - avesis.anadolu.edu.tr
Donepezil (DNP), an acetylcholinesterase (AChE) inhibitor, is one of the most preferred
choices in Alzheimer diseases (AD) therapy. In the present study, 38 new DNP analogues …

Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes

B SAĞLIK, S ILGIN, Y ÖZKAY - EUROPEAN JOURNAL OF …, 2016 - avesis.ogu.edu.tr
Donepezil (DNP), an acetylcholinesterase (AChE) inhibitor, is one of the most preferred
choices in Alzheimer diseases (AD) therapy. In the present study, 38 new DNP analogues …

Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes

BN Sağlık, S Ilgın, Y Özkay - European journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Donepezil (DNP), an acetylcholinesterase (AChE) inhibitor, is one of the most preferred
choices in Alzheimer diseases (AD) therapy. In the present study, 38 new DNP analogues …

Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes

BN Sağlık, S Ilgın, Y Özkay - European Journal of Medicinal Chemistry, 2016 - infona.pl
Donepezil (DNP), an acetylcholinesterase (AChE) inhibitor, is one of the most preferred
choices in Alzheimer diseases (AD) therapy. In the present study, 38 new DNP analogues …

Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes.

BN Sağlık, S Ilgın, Y Özkay - European Journal of Medicinal …, 2016 - europepmc.org
Donepezil (DNP), an acetylcholinesterase (AChE) inhibitor, is one of the most preferred
choices in Alzheimer diseases (AD) therapy. In the present study, 38 new DNP analogues …